盐酸苯环壬酯(L-Phencynonate Hydrochloride) - 药物靶点：mAChRs_在研适应症：晕动病，缺血性卒中，脑梗塞_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(L)-phencynonate、(L)-phencynonate hydrochloride、L-LPC

+ [14]

靶点

mAChRs

作用机制

mAChRs拮抗剂(毒蕈碱型乙酰胆碱受体家族拮抗剂)

治疗领域

其他疾病神经系统疾病心血管疾病+ [1]

在研适应症

晕动病缺血性卒中脑梗塞+ [1]

非在研适应症-

原研机构

北京四环制药有限公司

在研机构

中国人民解放军军事医学科学院毒物药物研究所

北京四环制药有限公司

北京华素制药股份有限公司

非在研机构

中国人民解放军军事科学院军事医学研究院

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)批准上市

特殊审评特殊审批 (中国)

登录后查看时间轴

结构

分子式C22H31NO3

InChIKeyROZOEEGFKDFEFP-JLPZCGHASA-N

CAS号230313-75-4

查看全部结构式(2)

关联

6

项与盐酸苯环壬酯相关的临床试验

NCT02241629 / Completed临床2期

Levo Phencynonate Hydrochloridefor the Prevention of Motion Sickness (Seasickness): a Randomized, Double-blind, Placebo Controlled, Multicenter,PhaseⅡClinical Study

A double-blind, randomized, placebo controlled, multicenter, dose-finding phaseⅡclinical superiority study.

开始日期2014-08-01

申办/合作机构

四環醫藥控股集團有限公司

CTR20140259 / Completed临床3期IIT

左旋盐酸苯环壬酯片预防晕动病（晕车）的随机、双盲、安慰剂和阳性药平行对照、多中心Ⅲ期临床试验

以安慰剂和盐酸苯环壬酯片为对照，进一步评价左旋盐酸苯环壬酯片预防晕动病（晕车）的有效性和安全性。

开始日期2014-03-29

申办/合作机构

中国人民解放军军事医学科学院毒物药物研究所

NCT02299804 / Completed临床2期

A Multicenter, Double-Blind, Phase Ⅱ Clinical Trial To Evaluate Efficacy And Safety Of Levophencynonate Hydrochloride In Patient With Vertigo Caused By Posterior Circulation Infarction

A Multicenter, Double-Blind, Placebo Controlled, Phase Ⅱa clinical trial to enroll 120 patients with Vertigo Caused By Posterior Circulation Infarction during 7 days, then to evaluate the efficacy of different dose of Levophencynonate Hydrochloric, and provide the effective dosage for phase IIb clinical study, to study the safety of Levophencynonate Hydrochloric.

开始日期2014-01-01

申办/合作机构

四環醫藥控股集團有限公司

100 项与盐酸苯环壬酯相关的临床结果

登录后查看更多信息

100 项与盐酸苯环壬酯相关的转化医学

登录后查看更多信息

100 项与盐酸苯环壬酯相关的专利（医药）

登录后查看更多信息

24

项与盐酸苯环壬酯相关的文献（医药）

2024-05-01·Chirality

The stereoselective pharmacokinetics of the desmethyl‐phencynonate hydrochloride in beagle dogs

Article

作者: Wang, Xiaoying ; Zhang, Zhenqing ; Xiong, Shan ; Yin, Lan ; Sun, Junying ; Li, Yuexin ; Li, Jinglai

AbstractThe aim of this study was to investigate the chiral inversion and the stereoselective pharmacokinetic profiles of desmethyl‐phencynonate hydrochloride after administration of the single isomer and its racemate to beagle dogs. A liquid chromatography with tandem mass spectrometry (LC–MS/MS) method was established for determination of the stereoisomers on chiral columns in beagle dog plasma, which met all the requirements. The chiral inversion in dogs of the desmethyl‐phencynonate hydrochloride were studied after administration of the single isomer or the racemic modification. The stereoselective pharmacokinetic profiles of the desmethyl‐phencynonate hydrochloride were studied by assays for simultaneous isomers after administration of the racemic modification. The results showed that the absorption of the Rconfiguration dosed as the single isomer was higher than it dosed as the racemic modification. The AUC(0‐t), AUC(0‐∞), and Cmax of the Sconfiguration were much higher than those of Rconfiguration after oral administration of the racemic desmethyl‐phencynonate hydrochloride. The chiral inversion of desmethyl‐phencynonate isomers could not occur in dogs after administration of the Rconfiguration.

2022-12-01·Annals of Surgical Oncology

Robotic Versus Laparoscopic Left and Extended Left Hepatectomy: An International Multicenter Study Propensity Score-Matched Analysis

Article

作者: Han, Ho-Seong ; Cheung, Tan-To ; Prieto, Mikel ; Chong, Charing C ; Lee, Jae-Hoon ; Lai, Eric C ; Sutcliffe, Robert P ; Choi, Sung Hoon ; Efanov, Mikhail ; Wang, Xiaoying ; Chong, Yvette ; Goh, Brian K P ; Park, James O ; Rayman, Shlomi ; Pratschke, Johann ; Scatton, Olivier ; Choi, Gi-Hong ; Kingham, T Peter ; Rotellar, Fernando ; Troisi, Roberto I ; Chiow, Adrian K H ; Tang, Chung-Ngai ; Liu, Rong ; Fuks, David ; Marino, Marco V ; D'Hondt, Mathieu ; Sucandy, Iswanto

BACKGROUNDControversies exist among liver surgeons regarding clinical outcomes of the laparoscopic versus the robotic approach for major complex hepatectomies. The authors therefore designed a study to examine and compare the perioperative outcomes of laparoscopic left hepatectomy or extended left hepatectomy (L-LH/L-ELH) versus robotic left hepatectomy or extended left hepatectomy (R-LH/R-ELH) using a large international multicenter collaborative database.METHODSAn international multicenter retrospective analysis of 580 patients undergoing L-LH/L-ELH or R-LH/R-ELH at 25 specialized hepatobiliary centers worldwide was undertaken. Propensity score-matching (PSM) was used at a 1:1 nearest-neighbor ratio according to 15 perioperative variables, including demographics, tumor characteristics, Child-Pugh score, presence of portal hypertension, multiple resections, histologic diagnosis, and Iwate difficulty grade.RESULTSBefore the PSM, 190 (32 %) patients underwent R-LH/R-ELH, and 390 (68 %) patients underwent L-LH/L-ELH. After the matching, 164 patients were identified in each arm without significant differences in demographics, preoperative variables, medical history, tumor pathology, tumor characteristics, or Iwate score. Regarding intra- and postoperative outcomes, the rebotic approach had significantly less estimated blood loss (EBL) (100 ml [IQR 200 ml] vs 200 ml [IQR 235 ml]; p = 0.029), fewer conversions to open operations (n = 4 [2.4 %] vs n = 13, [7.9 %]; p = 0.043), and a shorter hospital stay (6 days [IQR 3 days] vs 7 days [IQR 3.3 days]; p = 0.009).CONCLUSIONBoth techniques are safe and feasible in major hepatic resections. Compared with L-LH/L-ELH, R-LH/R-ELH is associated with less EBL, fewer conversions to open operations, and a shorter hospital stay.

2022-02-10·Evidence-Based Complementary and Alternative Medicine4区 · 医学

Efficacy and Safety of Lianhua Qingke Tablets in the Treatment of Mild and Common-Type COVID-19: A Randomized, Controlled, Multicenter Clinical Study

4区 · 医学

ArticleOA

作者: Yan, Xixin ; Mei, Jianqiang ; Liu, Qingquan ; Yuan, Yadong ; Wu, Lei ; Jiang, Rongmeng ; Gao, Yong ; Shang, Huanxia ; Xu, Xiaolong ; Hu, Jing ; Zhang, Ling ; Lian, Bo ; Wu, Shucai ; Zhang, Xin

Background. Lianhua Qingke (LH) tablets is an effective traditional Chinese medicine against various viral infections, especially in relieving coughing. However, its effects on COVID-19 are unknown. Methods. To examine the therapeutic effectiveness of LH tablets in COVID-19 patients with mild and common types, a randomized, multicenter, controlled study was carried out. COVID-19 cases were randomized to undergo routine treatment with or without LH tablets (4 tablets, three times a day) for 14 days. The primary endpoints were the rate of achieving clinical symptom resolution and the corresponding time. Results. There were 144 participants in the full analysis set (72 each in the LH and control groups). The LH group participants had elevated symptom alleviation rate at 14 days compared with control cases (FAS: 98.61% vs. 84.72%,

p

= 0.0026). In comparison with control group participants, the LH group participants had reduced median time to clinical symptom alleviation (median: 4 vs. 7 days,

p

< 0.0001). Higher resolution rates of coughing (98.44% vs. 84.51%,

p

= 0.0045) and expectoration (100% vs. 82.35%,

p

= 0.0268) were observed in the LH group. Times to recovery of fever (median: 2 vs. 3 days,

p

= 0.0007), coughing (median: 4 vs. 7 days,

p

< 0.0001), and expectoration (median: 3 vs. 6 days,

p

< 0.0001) were also notably shorter in the LH group. Moreover, the LH group had elevated improvement rates in chest computed tomography signs (FAS: 86.11% vs. 72.22%,

p

= 0.0402) and clinical cure at day 28 (FAS: 83.33% vs. 68.06%,

p

= 0.0326). However, no differences were found in the laboratory test and viral assay. Serious adverse events were not detected. Conclusion. These preliminary findings indicate LH tablets may be effective in symptomatic COVID-19, especially in relieving coughing. This trial was registered in Chinese Clinical Trial Registry (ChiCTR2100042069).

100 项与盐酸苯环壬酯相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	N05CM	DB16011

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
晕动病	中国	北京华素制药股份有限公司	-

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
缺血性卒中	临床2期	中国	北京四环制药有限公司	2016-05-05
缺血性卒中	临床2期	中国	中国人民解放军军事医学科学院毒物药物研究所	2016-05-05
脑梗塞	临床2期	中国	中国人民解放军军事医学科学院毒物药物研究所	2014-05-07
脑梗塞	临床2期	中国	北京四环制药有限公司	2014-05-07
眩晕	临床2期	中国	北京四环制药有限公司	2014-05-07
眩晕	临床2期	中国	中国人民解放军军事医学科学院毒物药物研究所	2014-05-07
脑梗塞	药物发现	中国	中国人民解放军军事科学院军事医学研究院	2014-05-07
眩晕	药物发现	中国	中国人民解放军军事科学院军事医学研究院	2014-05-07
晕动病	药物发现	中国	中国人民解放军军事医学科学院毒物药物研究所	2014-03-29